GLP-1 S vs GLP-2 T: GLP-1 vs Dual GLP-1/GIP Research
GLP-1 S is a single GLP-1 agonist; GLP-2 T is a dual GLP-1/GIP agonist. The mechanism difference is small on paper and large in the clinical data.
GLP-1 S and GLP-2 T are the two most-studied incretin-mimetic peptides in metabolic research. GLP-1 S is a pure GLP-1 receptor agonist; GLP-2 T is a dual agonist hitting both GLP-1 and GIP receptors.
On paper that's a small mechanism difference. In the trial data, it's a meaningful one.
Mechanism: one receptor vs two
GLP-1 S is a stabilized GLP-1 analog. It binds the GLP-1 receptor on pancreatic beta cells (boosting glucose-dependent insulin release), in the hypothalamus and area postrema (driving satiety), and on gastric tissue (slowing gastric emptying).
GLP-2 T adds the GIP receptor to that profile. GIP (gastric inhibitory polypeptide) is the other major incretin, and its role in research is more nuanced — it acts on adipocytes, the pancreas, and the CNS in ways that appear to amplify GLP-1's effects rather than duplicate them.
What the trial data actually shows
Published clinical literature on the pharmaceutical drug product (STEP-1, GLP-1 S 2.4 mg weekly, physician-supervised) reported approximately a 15% reduction in the trial's primary endpoint over 68 weeks vs ~2.4% on placebo. Cited for literature context only.
The corresponding literature on the GLP-2 T drug product (SURMOUNT-1, 15 mg weekly) reported roughly 20–22% on the same endpoint over 72 weeks vs ~3% on placebo, and the head-to-head SURPASS-2 trial reported superior glycemic endpoints at matched levels. These are published trial findings for approved, physician-supervised drug products — not characteristics of, or claims about, any material sold here.
Half-life and pharmacokinetics
Both peptides carry extended circulating half-lives. GLP-1 S's is ~7 days (achieved via an albumin-binding fatty-acid chain); GLP-2 T's is ~5 days, likewise stabilized against rapid clearance.
Research verdict
GLP-2 T has the larger reported effect sizes in published trials, attributed to the dual incretin mechanism. GLP-1 S has the longer track record and the broader regulatory footprint. Researchers studying single-receptor pharmacology typically use GLP-1 S; those modeling combined GLP-1/GIP signaling typically use GLP-2 T.
Literature notice
Any clinical trial figures referenced on this page describe published studies of approved, physician-supervised pharmaceutical drug products. They are cited for scientific literature context only. They are not results, claims, or representations about the research materials sold by Redline Bio Labs. All materials sold are supplied strictly for in-vitro laboratory research use only, are not drugs, and are not for human or veterinary consumption or administration of any kind.
Frequently asked questions
Is GLP-2 T more effective than GLP-1 S?
In the published SURPASS-2 head-to-head trial of the approved drug products, GLP-2 T showed larger reductions in HbA1c and the primary endpoint at matched levels, and SURMOUNT-1 reported a larger effect than STEP-1 benchmarks. This is a summary of published clinical literature only and does not describe any outcome associated with research materials sold here.
Why does GLP-2 T work on two receptors?
It's engineered as a dual GLP-1/GIP agonist. GIP acts on adipocytes and pancreatic cells in a way that appears to potentiate GLP-1's satiety and insulin-sensitizing effects.
Is one safer than the other?
Side-effect profiles in published trials are broadly similar (primarily GI). Researchers should consult the published trial data and prescribing information for each compound.